InvestorsObserver
×
News Home

Is aTyr Pharma Inc (LIFE) a Bad Choice in Biotechnology Wednesday?

Wednesday, March 20, 2024 09:40 AM | InvestorsObserver Analysts

Mentioned in this article

Is aTyr Pharma Inc (LIFE) a Bad Choice in Biotechnology Wednesday?

aTyr Pharma Inc (LIFE) is near the top in its industry group according to InvestorsObserver. LIFE gets an overall rating of 70. That means it scores higher than 70 percent of stocks. aTyr Pharma Inc gets a 84 rank in the Biotechnology industry. Biotechnology is number 19 out of 148 industries.

Overall Score - 70
LIFE has an Overall Score of 70. Find out what this means to you and get the rest of the rankings on LIFE!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With aTyr Pharma Inc Stock Today?

aTyr Pharma Inc (LIFE) stock is unchanged 0% while the S&P 500 is down -0.09% as of 4:00 PM on Tuesday, Mar 19. LIFE is unmoved $0.00 from the previous closing price of $2.00 on volume of 543 shares. Over the past year the S&P 500 is higher by 29.25% while LIFE has risen 3.09%. LIFE lost -$0.94 per share the over the last 12 months. Click Here to get the full Stock Report for aTyr Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App